Agree andrewk65 that they need to provide an update.
Even a warm and fuzzy shareholder letter will be a start!
Keytruda is great (for now) but different mode of action to what PYC is promising. Intracellular drug delivery is a MASSIVE advancement.
I can only hope that PYC will soon tell us that they have 3-5 candidates going into animal model studies for 2-3 different types of cancer animal models.
That would be superb from my point of view and the icing on the cake would be if they could confirm that Genentech is still maintaining a regular dialogue with them in relation to the CPPs they provided in 2015.
Price action is just taking it closer to fair value - my opinion of 2.5-3.5 cents per share.
Agree andrewk65 that they need to provide an update. Even a warm...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |